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Abstract 
Background: More severe cases of COVID‑ 19 are more likely to be hospitalized and around one‑fifth, needing ICU 
admission. Understanding the common laboratory features of COVID‑19 in more severe cases versus non‑severe 
patients could be quite useful for clinicians and might help to predict the model of disease progression. This sys‑
tematic review and meta‑analysis aimed to compare the laboratory test findings in severe vs. non‑severe confirmed 
infected cases of COVID‑19.
Methods: Electronic databases were systematically searched in PubMed, EMBASE, Scopus, Web of Science, and 
Google Scholar from the beginning of 2019 to 3rd of March 2020. Heterogeneity across included studies was deter‑
mined using Cochrane’s Q test and the I2 statistic. We used the fixed or random‑effect models to pool the weighted 
mean differences (WMDs) or standardized mean differences and 95% confidence intervals (CIs).
Findings: Out of a total of 3009 citations, 17 articles (22 studies, 21 from China and one study from Singapore) with 
3396 ranging from 12 to1099 patients were included. Our meta‑analyses showed a significant decrease in lympho‑
cyte, monocyte, and eosinophil, hemoglobin, platelet, albumin, serum sodium, lymphocyte to C‑reactive protein 
ratio (LCR), leukocyte to C‑reactive protein ratio (LeCR), leukocyte to IL‑6 ratio (LeIR), and an increase in the neutrophil, 
alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, blood urea nitrogen (BUN), creatinine 
(Cr), erythrocyte Sedimentation Rate (ESR), C‑reactive protein (CRP), Procalcitonin (PCT), lactate dehydrogenase (LDH), 
fibrinogen, prothrombin time (PT), D‑dimer, glucose level, and neutrophil to lymphocyte ratio (NLR) in the severe 
group compared with the non‑severe group. No significant changes in white blood cells (WBC), Creatine Kinase (CK), 
troponin I, myoglobin, IL‑6 and K between the two groups were observed.
Interpretation: This meta‑analysis provides evidence for the differentiation of severe cases of COVID‑19 based on 
laboratory test results at the time of ICU admission. Future well‑methodologically designed studies from other popu‑
lations are strongly recommended.
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Background
The coronavirus disease 2019 (COVID-19) outbreak 
started in December 2019 in China has spread sharply 
all over the world. Reports showed that more than 212 
countries and territories around the world are affected by 
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been more than 4000,000 confirmed reported COVID-19 
cases affected by and more than 280,000 reported deaths 
until May 13th [1]. While there are parallels between 
COVID-19 and the severe acute respiratory syndrome 
(SARS), variations in the clinical characteristics of the 
diseases caused by the two viruses have been noted [2]. 
Urgent identification of clinical laboratory predictors 
of disease progression toward severe/critical form is an 
urgent necessity for clinicians to be able to stratify risks, 
distinguish and differentiate severe patients from the 
mild/moderate form of COVID-19.
Based on the clinical symptoms and laboratory test 
results, patients are categorized as mild, moderate, 
severe, and critical types [2, 3]. Mild/moderate cases 
include most of the affected patients (81%). Although 
severe and critical ones comprise only 14% and 5% of 
infected cases, respectively [4] they mainly need hospital-
ization. Almost 20% of hospitalized patients need inten-
sive care unit (ICU) [5]. As such, the mortality rate of 
ICU admitted COVID-19 patients is reported quite high, 
nearly 61.5% die due to many different reasons [6].
Apart from the clinical symptoms and pulmonary 
computed tomography (CT) findings, a large number of 
COVID-19 confirmed patients showed laboratory fluctu-
ations including complete blood count (CBC) variables, 
cardiac and coagulation parameters, renal and liver func-
tion tests, and inflammation-related factors [7, 8].
Recently, combinations of some laboratory tests have 
been used in some settings to show the hyperinflamma-
tion state and prognosis. These combinations include 
neutrophil to lymphocyte ratio (NLR) and lymphocyte to 
C-reactive protein ratio (LCR) [9–11].
Among the CBC parameters of COVID-19 confirmed 
cases, decreased lymphocytes and normal or increased 
monocytes have pointed out previously [7]. Combined 
evidence so far appears inconsistent [6, 7, 12–15]. In 
the previous meta-analysis, the most prevalent labora-
tory features that were decreased in all confirmed cases 
consist of albumin, high CRP, high lactate dehydroge-
nase (LDH), lymphopenia, and high ESR, while increase 
in bilirubin, cytokines, and leukocytes was less frequent 
[5]. Since the pandemic outbreak of COVID-19, a vast 
number of studies investigated the laboratory changes in 
confirmed COVID-19 patients, leaving the association 
between the routine laboratory features and the disease 
severity as less attention subject. Therefore, in this study, 
we conducted a systematic review and meta-analysis to 
quantify the results of previously published studies, com-
paring the CBC indices cardiac and coagulation param-
eters, electrolyte factors, renal and liver function tests, 
inflammation-related factors, and some new combined 
inflammatory laboratory tests in severe/critical versus 
non-severe confirmed infected cases of COVID-19.
Methods
The Preferred Reporting Items for Systematic Reviews 
and Meta-analyses (PRISMA) guidelines were used for 
performing and reporting our systematic review and 
meta-analysis.
Search strategy
Electronic databases were systematically searched in 
PubMed, EMBASE, Scopus, Web of Science, and Google 
Scholar from the beginning of 2019 to 3rd of March 
2020. The reference lists of relevant studies and previous 
reviews manually were checked to retrieve more studies. 
Search terms included “2019 novel coronavirus infection” 
OR “COVID-19” OR “COVID19” OR “coronavirus dis-
ease 2019” OR “coronavirus disease-19” OR “2019-nCoV 
disease” OR “2019 novel coronavirus disease” OR “2019-
nCoV infection” OR “2019-nCoV” OR “2019 novel coro-
navirus” OR “2019 coronavirus” OR “novel coronavirus” 
OR (2019 AND coronavirus). Additional file  1: Appen-
dix 1 provides of search strategy from Scopus database.
Inclusion and exclusion criteria
Two independent researches (M.A-K and N.Z) assessed 
all retrieved reports using our inclusion and exclusion 
criteria. Differences were resolved through consensus 
or discussion with a third author (R.T). Studies that met 
the following criteria were included in our study: origi-
nal studies with cross-sectional, case–control, and cohort 
design in English language; studies that investigated 
laboratory features [includes CBC (neutrophil, lympho-
cyte, monocyte, eosinophil, hemoglobin, and platelet), 
liver and kidney functions [alanine aminotransferase 
(ALT), aspartate aminotransferase (AST), albumin, total 
bilirubin (TBIL), blood urea nitrogen (BUN), and creati-
nine (Cr)], myocardial enzymes [creatine kinase (CK), 
troponin I, and myoglobin], inflammatory factors [ESR, 
CRP, LDH, procalcitonin (PCT), and IL-6] serum electro-
lytes (sodium, potassium), coagulation functions [fibrin-
ogen, prothrombin time (PT), and D-dimer], and glucose 
level; we also combined inflammatory markers including 
NLR, LCR, leukocyte to C-reactive protein ratio (LeCR), 
and leukocyte to IL-6 ratio (LeIR). For a variable to be 
included in analysis, at least three studies that reported 
or appropriated to calculate the mean changes (standard 
deviation (SD)) of intended laboratory features in severe 
vs. non-severe COVID-19 were needed. Severe cases 
were defined based on severe cases of America thoracic 
society [16] or interim guidance of World Health Organi-
zation definition [17] or severe/critical case based on 
China’s National Health Commission definition [18] or 
Acute Respiratory Distress Syndrome (ARDS) based on 
Berlin definition [19] or admission to ICU. Otherwise, 
patients were defined as non-severe. We excluded studies 
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that were review, case report, case series, letter to editor, 
and abstracts without full text.
Data extraction
Two researchers (SMAK and NZ) were independently 
extracted the following data from the included studies: 
first author’s name, year of publication, type of publica-
tion, country, patient characteristics, total sample size, 
number of patients in severe and non-severe groups, 
mean (SD) of laboratory parameters in severe and non-
severe groups. Differences between the two researchers 
were resolved by consensus or discussion with a third 
author (PN-S).
Quality assessment
The quality of the included articles was critically assessed 
using the Newcastle–Ottawa Scale (NOS). This tool was 
conducted according to three aspects including selection, 
comparability, and exposure/outcome. A study with an 
NOS score of ≥ 7 was considered as good quality. Table 1 
shows the results of the quality assessment of included 
studies based on NOS.
Statistical analysis
All statistical analyses were performed using STATA ver-
sion 12.0 (Stata Corp., College Station, TX). Heterogene-
ity among included studies was assessed using Cochrane’s 
Q test or the I2 statistic. I2 above 70% and Cochrane’s Q 
test with P < 0.05 were considered as the existence of sig-
nificant heterogeneity.
Laboratory factors were estimated as the mean (SD) 
difference with 95% confidence intervals (CIs) between 
severe and non-severe groups. Weighted mean difference 
(WMD) with the random-effects model (DerSimonian–
Laird method) was used to pool the mean differences of 
each laboratory factors in studies with the same clinical 
units and measures; otherwise, the standardized mean 
difference (SMD) was applied. We used a series of sen-
sitivity analysis to assess the robustness of our findings; 
applying the leave-one-out method to test the impact of 
each included study on the pooled WMDs or SMDs. The 
potential evidence of publication bias was assessed using 
the Egger regression and Begg’s rank correlation tests.
Results
A total of 3009 citations were identified through elec-
tronic database searches. Of these, 1021 were duplicate 
reports. After screening titles and abstracts, 1694 articles 
were excluded and 294 full-text articles were retrieved 
for more assessment. Finally, 17 articles (or 22 studies) 
were found to be eligible for this meta-analysis. We sum-
marized the process of study identification and selection 
in Fig. 1.
All included articles were conducted in China [7, 
12–15, 20–26] except one that was performed in Singa-
pore [27]. Twenty-three studies of 17 articles included 
3396 (ranging from 12 to 1099) patients who were 720 
in severe and 2676 in non-severe groups. The number of 
studies with different laboratory tests is as following: 22 
studies were on lymphocyte, 21 on WBC, 18 on neutro-
phil and CRP, 17 on platelet, 15 on ALT, 14 on AST, Cr, 
and CK, 12 on albumin, PCT, and D-dimer, 11 on LDH, 
10 on monocyte, 9 on hemoglobin, TBIL, BUN, ESR, 
sodium, and potassium, 8 on PT, 6 on IL-6, 5 on eosino-
phil and troponin I, 4 on fibrinogen and glucose, and 3 
on myoglobin. Most studies clearly stated that data were 
basic (on admission/before treatment) laboratory test 
results [7, 12–14, 20–25, 27]. The study characteristics of 
these 23 included articles are presented in Table 1.
Main outcomes
The mean difference forest plots of laboratory features in 
severe vs. non-severe hospitalized patients with COVID-
19 are shown in Additional file 2: Appendix 2: 2a– h.
CBC with differential counts of WBC
Using random-effects model, our meta-analyses 
showed a significant decrease in the WMD of lym-
phocyte [WMD = − 0.43 × 109 per L; 95% CI − 0.56, 
− 0.30, P < 0.001; I2 = 90.1% (with 22 studies)], mono-
cyte [WMD = − 0.06 × 109 per L; 95% CI − 0.12, − 0.01, 
P = 0.032; I2 = 71.8% (with 10 studies)], and eosino-
phil [WMD = − 0.03 × 109 per L; 95% CI − 0.05, − 0.00, 
P = 0.037; I2 = 86.1% (with 5 studies)], hemoglobin 
[WMD = − 5.94  g/L; 95% CI − 8.23, − 3.64, P < 0.001; 
I2 = 0.0% (with 9 studies)], platelet [WMD = − 27.97 × 109 
per L; 95% CI − 39.60, − 16.35, P < 0.001; I2 = 55.8% (with 
17 studies)], and increased in the WMD of neutrophil 
[WMD = 0.74 × 109 per L; 95% CI 0.16, 1.33, P = 0.013; 
I2 = 74.6% (with 18 studies)], in the severe group com-
pared with the non-severe group. However, no signifi-
cant differences were found in WBC [WMD = 0.55 × 109 
per L; 95% CI − 0.09, 1.19, P = 0.094; I2 = 81.3% (with 21 
studies)] between the two groups were observed (Addi-
tional file 2: Appendix 2a, Fig: A–G).
Laboratory tests for liver and kidney function
The results indicated a significant decrease in the 
WMD of albumin [WMD = − 4.20  g/L; 95% CI − 5.99, 
− 2.41, P < 0.001; I2 = 73.9% (with 12 studies)], and 
increased in the WMD of ALT [WMD = 6.65 U/L; 
95% CI 4.21, 9.09, P < 0.001; I2 = 0.0% (with 15 RCTs)], 
AST [WMD = 11.91 U/L; 95% CI 8.29, 15.53, P < 0.001; 
I2 = 46.1% (with 14 studies)], TBIL [WMD = 0.08 mg/dL; 
95% CI 0.03, 0.14, P = 0.005; I2 = 0.0% (with 9 studies)], 
BUN [WMD = 2.34 mg/dL; 95% CI 0.66, 4.03, P = 0.006; 
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Table 1 Characteristics of included studies
a  study design whether stated clearly in methods or perceived from methods
Authors Publication year Country Sample size 
(severe/non-
severe)










Cai et al. 2020 China 58/240 Cross‑sectional Severe/non‑
severe
64 ± 7.41, 
40 ± 18.53
8 [12]
Cao (Min) et al. 2020 China 19/179 Single‑center 
cohort










Deng (a) et al. 2020 China 59/10 Cross‑sectional Severe/ordinary 61.4 ± 16.7 (all 
patients)
4 [7]
Deng (b) et al. 2020 China 36/9 Cross‑sectional ICU/ordinary 
cases
61.4 ± 16.7 (all 
patients)
4 [7]
Guan et al. 2020 China 173/926 Cohort Severe/non‑
severe
52 ± 18.53, 
45 ± 17.05
6 [20]
Huang et al. 2020 China 13/28 Cohort ICU/Non‑ICU 49 ± 14.82, 
49 ± 12.23
5 [7]





52 ± 11.86, 
44 ± 11.86
3 [21]














56 ± 9.75, 
41 ± 18.75
5 [23]
Liu (Songqiao) (a) 
et al.
















60.09 ± 13.86, 
44.47 ± 15.62
9 [20]
Liu (Yanli) et al. 2020 China 26/56 Retrospective 
study
ARDS/Non‑ARDS 61 ± 13.34, 
49 ± 13.34
8 [24]




ICU/Non‑ICU 66 ± 15.57, 
51 ± 18.53
7 [25]




Did not require 
supplemental 
O2
56 ± 6.5, 37 ± 6.25 6 [27]
Zhang (Fengqin) 
(a) et al.
2020 China 9/23 Retrospective 
single center





2020 China 26/23 Retrospective 
single center





2020 China 58/82 Cross‑sectional Severe/non‑
severe patients
64 ± 15.5, 
51.5 ± 13
6 [22]
Zheng (a) et al. 2020 China 3/71 Cross‑sectional Severe or criti‑
cal)/non‑severe
67.875 ± 12.22, 
44.845 ± 16.79
5 [15]
Zheng (b) et al. 2020 China 3/9 Cross‑sectional Severe or critical/
Mild
67.875 ± 12.22, 
39.444 ± 14.32
5 [15]
Zheng (c) et al. 2020 China 2/15 Cross‑sectional Severe and criti‑
cal/asympto‑
matic infected
67.875 ± 12.22, 
32.667 ± 22.68
5 [15]





76 ± 6.67, 
77 ± 8.15
8 [25]
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I2 = 39.3% (with 9 studies)], and Cr [WMD = 0.08 mg/dL; 
95% CI 0.03, 0.12, P < 0.001; I2 = 0.0% (with 14 studies)] 
in the severe group compared with the non-severe group 
(Additional file 2: Appendix 2b, Fig: A–F).
Myocardial enzymes and myoglobin
The pooled findings showed no significant differ-
ences between the two groups of COVID-19 patients 
on myocardial enzymes and myoglobin, including CK 
[WMD = − 3.01 U/L; 95% CI − 12.91, 6.90, P = 552; 
I2 = 51.7% (with 14 studies)], troponin I [SMD = 0.27; 
95% CI − 0.14, 0.67, P = 0.193; I2 = 77.3% (with 5 stud-
ies)], and myoglobin [WMD = 8.11  ng/mL; 95% CI 
− 6.10, 22.33, P = 0.263; I2 = 73.2% (with 3 studies)] 
(Additional file 2: Appendix 2c, Fig: A–C).
Records idenfied through 
database searching 
(n = 3009): PubMed (891), Scopus 













Addional records idenfied 
through other sources 
(n = 0)








excluded, with reasons 
(n = 277)
Animal (n = 1)
Abstract (n = 17)
Duplicate date (n = 1)
Editorial (n = 38)
Full text not found (n = 1)
Non-english (n = 18)
Non-relevant (n = 47)
Not reported intended 
outcomes (n = 108)
Review (n = 5)
Study protocol (n = 5)
Without intended groups (n 
= 36)






Fig. 1 The process of study identification and selection
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Inflammatory markers
Our findings of inflammatory markers showed a signifi-
cant increase in the WMD of ESR [WMD = 27.67 mm/h; 
95% CI 22.94, 32.40, P < 0.001; I2 = 22.3% (with 9 studies)], 
CRP [WMD = 36.61 mg/L; 95% CI 24.40, 48.82, P < 0.001; 
I2 = 91.9% (with 18 studies)], LDH [WMD = 102.15 U/L; 
95% CI 72.76, 131.53, P < 0.001; I2 = 50.3% (with 11 stud-
ies)], and PCT [WMD = 0.03  ng/mL; 95% CI 0.00, 0.06, 
P = 0.043; I2 = 41.1% (with 12 studies)] in the severe 
group compared with the non-severe group. While no 
significant changes were observed in IL-6 [SMD = 0.54; 
95% CI − 0.37, 1.45, P = 0.243; I2 = 95.5% (with 6 studies)] 
between the two groups (Additional file 2: Appendix 2d, 
Fig: A–E).
Serum electrolytes
The pooled results of serum electrolytes among 
severe compared to non-severe patients indi-
cated a significant decrease in the WMD of sodium 
[WMD = − 1.95  mmol/L; 95% CI − 2.87, − 1.03, 
P < 0.001; I2 = 75.5% (with 9 studies)], but non-significant 
difference on potassium [WMD = − 0.07  mmol/L; 95% 
CI − 0.18, 0.04, P = 0.206; I2 = 34.3% (with 9 studies)] 
(Additional file 2: Appendix 2e, Fig: A and B).
Laboratory tests for coagulation functions
Pooled findings on laboratory tests for coagulation func-
tions showed a significant increase in the WMD of fibrin-
ogen [WMD = 0.80  g/L; 95% CI 0.32, 1.28, P = 0.001; 
I2 = 82.2% (with 4 studies)], PT [WMD = 0.63  s; 95% 
CI 0.27, 0.99, P = 0.001; I2 = 69.2% (with 8 studies)], 
and D-dimer [WMD = 0.18  mg/L; 95% CI 0.10, 0.27, 
P < 0.001; I2 = 99.3% (with 12 studies)] in severe vs. non-
severe hospitalized patients (Additional file  2: Appen-
dix 2f, Fig: A–C).
Glucose level
We found a significant increase in glucose levels among 
the severe patients [WMD = 12.43 s; 95% CI 1.95, 22.91, 
P = 0.020; I2 = 0.0% (with 4 studies)] when compared with 
non-severe patients (Additional file 2: Appendix 2 g, Fig: 
A).
Combined markers
The pooled findings on the new combined mark-
ers showed a significant increase in the SMD of NLR 
[SMD = 0.23; 95% CI 0.08, 0.37, P = 0.002; I2 = 14.6% 
(with 18 studies)] and a decrease in LCR [SMD = − 8.12; 
95% CI − 10.05, − 6.18, P = 0.001; I2 = 98.6% (with 
18 studies)], LeCR [SMD = − 1.47; 95% CI − 2.13, 
− 0.80, P = 0.001; I2 = 94.6% (with 17studies)], and 
(LeIR) [SMD = − 0.99; 95% CI − 1.98, − 0.00, P = 0.049; 
I2 = 93.6% (with 5 studies)] in severe vs. non-severe 
hospitalized patients infected by COVID-2019 (Addi-
tional file 2: Appendix 2 h, Fig: A–D).
Table  2 shows a summary of laboratory features 
in severe vs. non-severe hospitalized patients with 
COVID-19.
Sensitivity analysis
We evaluated the effect of each study on the strength 
of the pooled WMDs or SMDs by excluding each study 
from the meta-analysis. We found no significant dif-
ferences between the pre- and post-sensitivity pooled 
effect sizes for lymphocyte, hemoglobin, platelet, neutro-
phil, albumin, ALT, AST, TBIL, BUN, Cr, CK, troponin 
I, myoglobin, ESR, CRP, LDH, IL-6, sodium, fibrinogen, 
PT, D-dimer, glucose level, NLR, LCR, and LeCR. How-
ever after omitting Liu (Spngqiao) (a) et al. [20], the study 
on monocyte, (WMD = − 0.04, 95% CI − 0.10, 0.01), 
Liu (Spngqiao) et  al. (b) [20] the study on eosinophil 
(WMD = − 0.02, 95% CI − 0.06, 0.01), Guan et  al. [20], 
the study on WBC (WMD = 0.65, 95% CI 0.02, 1.27), Liu 
(Yanli) et al. [24], the study on PCT (WMD = 0.02, 95% 
CI − 0.004, 0.05), Huang et al. [7], the study on potassium 
(WMD = − 0.10, 95% CI − 0.18, − 0.02), and Deng et al. 
(b) [7], the study on LeIR (SMD = − 0.52, 95% CI − 1.35, 
0.31), we found significant differences between pre- and 
post-sensitivity pooled effect sizes.
Publication bias
The Egger’s regression and Begg’s rank correlation tests 
were performed to detect potential publication bias. 
These indicated no significant publication bias for lym-
phocyte, monocyte, eosinophil, hemoglobin, platelet, 
neutrophil, albumin, AST, ALT, TBIL, BUN, Cr, CK, 
troponin I, myoglobin, ESR, LDH, PCT, IL-6, potas-
sium, fibrinogen, PT, D-dimer, glucose, NLR, LeCR, and 
LeIR. Because there was evidence of publication bias 
on WBC [Egger (p < 0.01), Begg (P = 0.13)], CRP [Egger 
(p < 0.01), Begg (P < 0.01)], sodium [Egger (p = 0.02), Begg 
(P = 0.29)], and LCR [Egger (p < 0.01), Begg (P < 0.01)], 
we conducted the non-parametric method (Duval and 
Tweedie) to estimate the findings of censored studies. 
There were no significant differences between before and 
after including censored studies for WBC, sodium, and 
LCR but not for CRP [before (WMD = 36.61 mg/L; 95% 
CI 24.40, 48.82) and after (WMD = 12.21 mg/L; 95% CI 
− 1.28, 25.84)].
Discussion
To the best of authors’ knowledge, this is the first meta-
analysis that elaborated on the differences between labo-
ratory tests results of severe and non-severe confirmed 
cases of COVID-19. The results showed the significant 
decreased levels of lymphocyte, monocyte, eosinophil, 
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hemoglobin, and platelet, while elevated neutrophil 
counts among the CBC indices in severe vs. non-severe 
patients. ALT, AST, TBIL, BUN, and Cr levels showed 
the significant increase, following a decrease in albumin 
level as the main liver and kidney outcomes in severe 
patients compared to non-severe ones. Inflammatory/
infection markers (ESR, CRP, LDH, and PCT, but not 
IL-6), coagulation function tests (fibrinogen, PT, and 
D-dimer), and glucose were positively associated with the 
COVID-19 severity. However, serum sodium decreased 
in severe patients in comparison with non-severe group. 
Besides, potassium, and other cardiac-related factors 
were not associated with COVID-19 severity. It is worth 
to mention that combined ratios significantly decreased 
(LCR, LeCR, and LeIR6) and increased (NLR) in severe/
critical compared to non-severe COVID-19 patients. The 
laboratory features presented by this meta-analysis could, 
to a large extent, be attributed to low oxygen saturation, 
respiratory failure, septic shock, and/or multiple organ 
dysfunction or failure compatible with the ARDS course 
of severe and critical COVID-19 types [2, 3].
COVID-19 is a systemic disorder affecting multiple 
organs. Abnormal kidney and liver function test results 
and elevated serum glucose might happen in more 
severe cases due to the following explanations. These 
include, but not limited to hypoxia, hypoperfusion as 
Table 2 Laboratory features in severe vs. non-severe hospitalized patients with COVID-19
HB, hemoglobin; WBC, white blood cell; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBIL, total bilirubin; BUN, blood urea nitrogen; Cr, Creatine; 
ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; IL-6, interleukin 6
Outcomes Severe groups vs. non-severe groups
No Pooled WMD (95% CI) Heterogeneity 
(I2%, Pa)
Lymphocyte 22 − 0.43 (− 0.56, − 0.30) 90.1%, 0.000
Monocyte 10 − 0.06 (− 0.12, − 0.01) 71.8%, 0.000
Eosinophil 5 − 0.03 (− 0.05, − 0.00) 86.1%, 0.000
Hb 9 − 5.94 (− 8.23, − 3.64) 0.0%, 0.952
Platelet 17 − 27.97 (− 39.6, − 16.35) 55.8%, 0.003
Neutrophil 18 0.74 (0.16, 1.33) 74.6%, 0.000
WBC 21 0.55 (− 0.09, 1.19) 81.3%, 0.000
Albumin 12 − 4.20 (− 5.99, − 2.41) 73.9%, 0.000
ALT 15 6.65 (4.21, 9.09) 0.0%, 0.492
AST 14 11.91 (8.29, 15.53) 46.1%, 0.030
TBIL 9 0.08 (0.03, 0.14) 0.0%, 0.953
BUN 9 2.34 (0.66, 4.03) 39.3%, 0.106
Cr 14 0.08 (0.03, 0.12) 0.0%, 0.930
Creatine kinase 14 − 3.01 (− 12.91, 6.90) 51.7%, 0.013
Troponin I 5 0.27 (− 0.14, 0.67) 77.3%, 0.001
Myoglobin 3 8.11 (− 6.10, 22.33) 73.2%, 0.024
ESR 9 27.67 (22.94, 32.40) 22.3%, 0.245
CRP 18 36.61 (24.40, 48.82) 91.9%, 0.000
Lactate dehydrogenase 11 102.15 (72.76, 131.53) 50.3%, 0.028
Procalcitonin 12 0.03 (0.00, 0.06) 41.1%, 0.067
IL‑6 6 0.54 (− 0.37, 1.45) 95.5%, 0.000
Sodium 9 − 1.95 (− 2.87, − 1.03) 75.5%, 0.000
Potassium 9 − 0.07 (− 0.18, 0.04) 34.3%, 0.144
Fibrinogen 4 0.8 (0.32, 1.28) 82.2%, 0.001
Protrombine 8 0.63 (0.27, 0.99) 69.2%, 0.002
D‑dimer 12 0.18 (0.10, 0.27) 99.3%, 0.000
Glucose level 4 12.43 (1.95, 22.91) 0.0%, 0.433
Neutrophil‐to‐Lymphocyte ratio 18 0.23 (0.08, 0.37) 14.6%, 0.279
Lymphocyte‑to‑C‑reactive protein ratio 18 − 8.12 (− 10.05, − 6.18) 98.6%, 0.000
Leukocyte‑to‑C‑reactive protein ratio 17 − 1.47 (− 2.13, − 0.80) 94.6%, 0.000
Leukocyte‑to‑IL‑6 ratio 5 − 0.99 (− 1.98, − 0.00) 93.6%, 0.000
Page 8 of 10Ghahramani et al. Eur J Med Res           (2020) 25:30 
well as thrombosis caused by ARDS, shock and dissem-
inated intravascular coagulation respectively. Aggra-
vation of underlying disease in severe cases that are 
older and suffer from concomitant comorbidities also 
is another possibility for this feature. Drug-induced 
damages [23] to the liver are also one potential fac-
tor. Secondary hemophagocytic lymphohistiocytosis 
(HLH) characterized by hypercytokinemia with multi-
organ failure [28] which occurred after viral infection 
in adults [29, 30] is another possible explanation for 
the stated laboratory features. Although one no peer-
reviewed study by Zheng et  al. [15] has demonstrated 
that organ damage in COVID-19 is mostly endorsed 
as organ damage caused by the virus itself rather than 
HLH. This claim needs more investigation and autopsy 
studies.
Myocardial damage in COVID-19, especially in severe 
cases, has been demonstrated previously [22, 24]; how-
ever, our analysis did not find significant higher level of 
myocardial enzymes in severe compared to non-severe 
cases. We believe more studies on the pathophysiology of 
such injury may help this issue to be clearer, one possibil-
ity could be interstitial infiltration of mononuclear cells 
instead of direct damage of myocardium in severe cases 
[23] which it is not in line with the finding of Zheng et al. 
[15].
The present findings showed a decreased in lym-
phocyte, eosinophil and monocyte counts but slightly 
increased of neutrophil in severe cases. Lymphopenia 
as a dysregulation in the immune response is mapped 
through more decrease in T cell and especially T helper 
cells in severe cases of COVID-19 [31]. The mechanism 
of this lymphopenia seems to be both due to the cyto-
toxic action of virus [6] and the collective characteristics 
of severe patients which are more likely to be older and 
have underlying diseases [24, 26, 32] which make them 
more susceptible to endothelial dysfunction and its cor-
related lymphopenia [33]. Findings of current study on 
decreased eosinophil and monocytes but increased neu-
trophils in severe cases need more investigations through 
future studies. These results highlight the potential of 
simple available tests besides the lymphocytes count 
for early screening in severe and critically ill COVID-19 
cases.
The NLR was a commonly used index for determin-
ing the bacterial infections severity and for the prognosis 
of pneumonia and tumor patients [34, 35]. The current 
study suggests the increased NLR and decreased LCR 
of severe COVID-19 patients in which been recently 
reported [36] but to the best of our knowledge, our meta-
analysis for the first time showed decrease in LeCR, and 
LeIR in severe COVID-19 patients compared to non-
severe, indicating the poor prognosis of this pneumonia.
Lower hemoglobin level in more severe cases could be 
due to underlying medical conditions, malnutrition or 
coagulation abnormality. Coagulation abnormality is also 
contained in low platelet count, increased fibrinogen, 
D-dimer level and prolonged PT in severe patients.
An increase in PCT and neutrophil may be correlated 
with the concomitant bacterial infection in severe cases. 
Therefore, high PCT and neutrophil in two laboratory 
tests might be beneficial for the prognosis of severe cases. 
Despite that our meta-analysis found higher levels of 
ESR, CRP and LDH as inflammatory markers in severe 
cases of COVID-19, the results did not show increased 
IL-6 level in severe cases. This finding was mainly 
affected by the results of the study by Liu et al. [37] and 
should be confirmed with more investigations on IL-6 as 
well as other cytokines and chemokines.
Our findings provide evidence for the differentiation 
of severe cases of COVID-19 based on laboratory test 
results collected at the admission time. Our results also 
may provide the potential for efficient resource allocation 
in the era of scarcity of available resources including ICU.
However, inadequate evidence from outside China [27] 
may limit the generalizability of our results especially in 
terms of availability of the costly laboratory tests in low 
resource settings. Accordingly, as more data become 
available from outside of China in the ongoing weeks, 
it is highly recommended that new data are interpreted 
and compared with the present findings as the virus may 
differently affect based on both genetic and/or interplay 
environmental factors diversity. Moreover, heterogeneity 
of included studies as another limitation implies the need 
for further studies.
Conclusions
In summary, our meta-analysis provides evidence for the 
differentiation of severe and non-severe cases of COVID-
19 based on the laboratory test results on the time of 
admission. The results of CBC test, liver and kidney func-
tion tests, inflammatory/infection markers, serum elec-
trolytes and glucose were significantly different between 
severe and non-severe cases of COVID-19. However, to 
confirm our results, we think further studies, particularly 
from other populations, are needed.
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